LncRNA MCM3AP-AS1 inhibits cell proliferation in cervical squamous cell carcinoma by down-regulating miRNA-93.
MCM3AP-AS1
cervical squamous cell carcinoma
miR-93
proliferation
survival
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
28 02 2020
28 02 2020
Historique:
received:
30
10
2019
revised:
02
01
2020
accepted:
06
01
2020
pubmed:
28
1
2020
medline:
17
3
2021
entrez:
28
1
2020
Statut:
ppublish
Résumé
MCM3AP antisense RNA 1 (MCM3AP-AS1) is characterized as an oncogenic lncRNA in hepatocellular carcinoma and glioblastoma. We analyzed TCGA dataset and observed the down-regulation of MCM3AP-AS1 in cervical squamous cell carcinoma (CSCC). The present study was therefore performed to investigate the role of MCM3AP-AS1 in CSCC. A total of 64 female patients with CSCC (38-68 years old; mean age: 53.1 ± 6.5 years old) were enrolled in the present study. RT-qPCR was performed to evaluate gene expression. Methylation specific PCR (MSP) was performed to assess the methylation of miR-93 gene after the overexpression and silencing of MCM3AP-AS1. Cell transfections were performed to investigate the interactions between MCM3AP-AS1 and miR-93. Cell proliferation was assessed by CCK-8 assay. The results showed that MCM3AP-AS1 was down-regulated in CSCC and predicted poor survival. The expression levels of MCM3AP-AS1 were inversely correlated with the expression levels of miR-93. Overexpression of MCM3AP-AS1 led to down-regulation of miR-93, while silencing of MCM3AP-AS1 played an opposite role in CSCC cells. Methylation-specific PCR revealed that MCM3AP-AS1 could positively regulate the methylation of miR-93 gene. Cell proliferation analysis showed that overexpression of MCM3AP-AS1 led to reduced proliferation rate of CSCC cells. Silencing of MCM3AP-AS1 played an opposite role and overexpression of miR-93 reduced the effects of overexpressing MCM3AP-AS1. Therefore, MCM3AP-AS1 may inhibit cell proliferation in CSCC by down-regulating miRNA-93.
Sections du résumé
BACKGROUND
MCM3AP antisense RNA 1 (MCM3AP-AS1) is characterized as an oncogenic lncRNA in hepatocellular carcinoma and glioblastoma. We analyzed TCGA dataset and observed the down-regulation of MCM3AP-AS1 in cervical squamous cell carcinoma (CSCC). The present study was therefore performed to investigate the role of MCM3AP-AS1 in CSCC.
METHODS
A total of 64 female patients with CSCC (38-68 years old; mean age: 53.1 ± 6.5 years old) were enrolled in the present study. RT-qPCR was performed to evaluate gene expression. Methylation specific PCR (MSP) was performed to assess the methylation of miR-93 gene after the overexpression and silencing of MCM3AP-AS1. Cell transfections were performed to investigate the interactions between MCM3AP-AS1 and miR-93. Cell proliferation was assessed by CCK-8 assay.
RESULTS
The results showed that MCM3AP-AS1 was down-regulated in CSCC and predicted poor survival. The expression levels of MCM3AP-AS1 were inversely correlated with the expression levels of miR-93. Overexpression of MCM3AP-AS1 led to down-regulation of miR-93, while silencing of MCM3AP-AS1 played an opposite role in CSCC cells. Methylation-specific PCR revealed that MCM3AP-AS1 could positively regulate the methylation of miR-93 gene. Cell proliferation analysis showed that overexpression of MCM3AP-AS1 led to reduced proliferation rate of CSCC cells. Silencing of MCM3AP-AS1 played an opposite role and overexpression of miR-93 reduced the effects of overexpressing MCM3AP-AS1.
CONCLUSIONS
Therefore, MCM3AP-AS1 may inhibit cell proliferation in CSCC by down-regulating miRNA-93.
Identifiants
pubmed: 31985002
pii: 221953
doi: 10.1042/BSR20193794
pmc: PMC7007402
pii:
doi:
Substances chimiques
MIRN93 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 The Author(s).
Références
Tumour Biol. 2016 Mar;37(3):2779-88
pubmed: 26715267
PLoS Pathog. 2019 May 22;15(5):e1007769
pubmed: 31116803
Cancer Med. 2016 Dec;5(12):3512-3519
pubmed: 27794184
Urol Oncol. 2019 Feb;37(2):150-157
pubmed: 30455080
Front Mol Neurosci. 2018 Jan 09;10:437
pubmed: 29375300
Noncoding RNA Res. 2016 Nov 11;1(1):69-76
pubmed: 30159413
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Obstet Gynecol. 2013 Aug;122(2 Pt 1):393
pubmed: 23969811
PLoS Pathog. 2019 Feb 28;15(2):e1007442
pubmed: 30818369
PLoS Pathog. 2019 Jun 21;15(6):e1007835
pubmed: 31226168
PLoS Pathog. 2019 May 13;15(5):e1007755
pubmed: 31083694
Mol Cancer. 2019 Feb 19;18(1):28
pubmed: 30782188
Cancer. 2017 Jul 1;123(13):2404-2412
pubmed: 28464289
BJOG. 2015 Jan;122(1):119-27
pubmed: 25229645
World J Gastroenterol. 2011 Nov 14;17(42):4711-7
pubmed: 22180714
Vaccine. 2011 Mar 16;29(13):2487-94
pubmed: 21211586
PLoS Pathog. 2019 Apr 19;15(4):e1007575
pubmed: 31002735
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593